F.122. Toll Like Receptor 2 Promotes Th2/Th17 Responses via TLR4 and TLR8 by Human Dendritic Cells by Abrogating the Type 1 Interferon Amplification Loop (original) (raw)

3.9)%,p b 0.05];CD4+CD8+ THY vs Tx[Tx:39.9(5.6)/SRL:23.4 (36.3)/FTY:33.4(10.2)/FTY+SRL:18.3(4.7)x106,p b 0.005], Ly in PB vs Tx and SRL[Tx:63.0(27.0)/SRL:50.0(14.8)/FTY:15.0 (5.0)/FTY+SRL:17.0(4.3)%,p b 0.005];CD11b+ cells in the allografts vs FTY[Tx:8.8(9.2)/SRL:7.2(6.2)/FTY:14.1(22.1)/ FTY+SRL:4.6(2.4)%,p b 0.05];higher counts of CD11b+ non-Ly in SPL vs Tx[Tx:42.9(18.2)/SRL:22.6(6.0)/FTY:21.7(5.0)/FTY+ SRL:20.7(7.1)x106,p b 0.005]; CD11b+ lymphocytes vs Tx and SRL in PB[Tx:6.0(3.5)/SRL:7.3(7.4)/FTY:50.7(3.3)/FTY+ SRL:43.5(10.6)%,p b 0.005];CD11b+ non-Ly vs Tx and SRL in PB [Tx:42.7(28.7)/SRL:56.5(42.4)/FTY:93.5(9.8)/FTY+SRL:93.4 (1.5)%,pb 0.005].Increased allograft survival in FTY+SRL was associated with decreased peripheral and allograft-infiltrating immune cells.